BCLI has 36-month beta value of 0.13. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BCLI is 7.64M, and currently, short sellers hold a 6.06% ratio of that float. The average trading volume of BCLI on July 09, 2025 was 1.40M shares.
BCLI) stock’s latest price update
Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI)’s stock price has plunge by 14.91%relation to previous closing price of $1.14. Nevertheless, the company has seen a 16.96% surge in its stock price over the last five trading sessions. prnewswire.com reported 2025-07-08 that BrainStorm to Continue with Planned Phase 3b Trial and Remains Committed to Advancing Access for People Living with ALS NEW YORK, July 8, 2025 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today acknowledged that the U.S. Food and Drug Administration’s (FDA) consideration of a Citizen Petition requesting a new review of the data supporting NurOwn will provide a critical opportunity to reaffirm its potential as therapy for amyotrophic lateral sclerosis (ALS). A Citizen Petition, submitted to the FDA under the Federal Food, Drug, and Cosmetic Act (21 CFR § 10.30), is a regulatory process that allows any interested party to formally request the Agency to take action on specific matters, such as reviewing data, issuing new guidance, or taking enforcement action.
BCLI’s Market Performance
Brainstorm Cell Therapeutics, Inc (BCLI) has experienced a 16.96% rise in stock performance for the past week, with a 15.93% rise in the past month, and a 13.90% rise in the past quarter. The volatility ratio for the week is 7.46%, and the volatility levels for the past 30 days are at 8.31% for BCLI. The simple moving average for the last 20 days is 10.88% for BCLI stock, with a simple moving average of -21.05% for the last 200 days.
Analysts’ Opinion of BCLI
Many brokerage firms have already submitted their reports for BCLI stocks, with Maxim Group repeating the rating for BCLI by listing it as a “Buy.” The predicted price for BCLI in the upcoming period, according to Maxim Group is $12 based on the research report published on February 04, 2021 of the previous year 2021.
Maxim Group gave a rating of “Buy” to BCLI, setting the target price at $6 in the report published on December 19th of the previous year.
BCLI Trading at 11.62% from the 50-Day Moving Average
After a stumble in the market that brought BCLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.69% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCLI starting from Lebovits Chaim, who purchase 1,836 shares at the price of $3.43 back on Oct 01 ’24. After this action, Lebovits Chaim now owns 80,960 shares of Brainstorm Cell Therapeutics, Inc, valued at $6,292 using the latest closing price.
Lebovits Chaim, the President & CEO of Brainstorm Cell Therapeutics, Inc, purchase 22,000 shares at $0.23 during a trade that took place back on Sep 30 ’24, which means that Lebovits Chaim is holding 1,186,865 shares at $5,016 based on the most recent closing price.
Stock Fundamentals for BCLI
The total capital return value is set at 1.68.
Based on Brainstorm Cell Therapeutics, Inc (BCLI), the company’s capital structure generated -0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -4.33.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.21.
Conclusion
To put it simply, Brainstorm Cell Therapeutics, Inc (BCLI) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
